ProtAffin Biotechnologie, AG: Series B €4.0M

ProtAffin Biotechnologie (Austria) is focused on developing novel biotechnology therapeutic products for acute and chronic inflammatory diseases has closed a €4.0M Series A financing. Participants include The Entrepreneurs Fund BV, Aescap Venture Management and Z-Cube.

ChemoCentryx, Inc.: Series D $29.9M

ChemoCentryx (Mountain View, CA) a developer of drugs for autoimmune diseases, inflammatory diseases and oncology with lead indications for inflammatory bowel disease and multiple sclerosis, closed a $29.9M Series D finanicing. The deal was led by the Glaxo Group Ltd. and was joined by Alta Partners, GIMV, HBM BioVentures and OrbiMed Advisors.

Nitec Pharma AG.: Series B $26M

Nitec Pharma (Switzerland) a drug company focused on the treatment of chronic inflammatory diseases with lead indications in Rheumatoid Arthritis and Polymylagia Rheumatica, raised $26M Series B round. The deal was led by NGN Capital other participants included Atlas Venture and Global Life Science Ventures.

Amira Pharmaceuticals, Inc.: Series B $25M

Amira Pharmaceuticals (San Diego, CA) drug company focused on inflammatory respitory and cardiovascular disease solutions via the leukotriene and TNFα pathways closed a $25M Series B financing. The deal was led by Novo AS and joined by Avalon Ventures, Prospect Venture Partners and Versant Ventures.

Tragara Pharma, Inc.: Series A $40M

Tragara (San Diego, CA) a pharmaceutical company developing therapies for the treatment of lung cancer and inflammatory diseases closed a $40M Series A round. The financing was led by Domain Associates, ProQuest Investments, Morgenthaler Ventures, Oxford Bioscience Partners and Mitsubishi International Corporation.

Calistoga Pharma, Inc.: Series A $21M

Calistoga Pharmaceuticals (Seattle, WA) a drug development startup focused on oncology and inflammation raised a $21M Series A. The deal was led by Frazier Healthcare Ventures and was joined by Alta Partners, Three Arch Partners and Amgen Ventures.

Cara Therapeutics, Inc.: Series C $24M

Cara Therapeutics (Tarrytown, NY) is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation has closed a $24M Series C financing. Investors included Scottish Widows Investment Partnership, Mitsubishi International Corporation, MVM Life Science Partners, Alta Partners and Ascent Biomedical Ventures.

Ception Therapeutics Inc.: Series C $63M

Ception Therapeutics (Malvern, PA) a drug company developing anti-inflammatories, raised a $63M Series C round. The financing was led by Essex Woodlands Health Ventures, and was joined by Investor Growth Capital, MDS Life Sciences, New Science Ventures and Aperture Venture Partners.

Conatus Pharma, Inc.: Series A $6.6M

Conatus Pharmaceuticals (San Diego, CA) a drug developer focused on liver disease, has secured $6.62 million of a $27.37M Series A round. Participants include Aberdare Ventures, Bay City Capital, Advent International and Hale BioPharma Ventures.